. Author manuscript; available in PMC: 2014 Nov 13.

Published in final edited form as: Sci Signal. 2014 May 13;7(325):ra44. doi: 10.1126/scisignal.2005261

Table 3.

Properties of liposomes containing cisplatin.

Liposomal formulation	Mean z_avgd_h (nm) ± SEM	PDI	Encapsulation efficiency (%)	w/w % (drug/lipid)
CFP	183 ± 12	0.16	C: 62	C: 11
CAFP	177 ± 6	0.06	C: 58	C: 9.9
			A: 73	A: 5.2
CEFP	183 ± 13	0.16	C: 60	C: 10.5
			E: 34	E: 2.4
CGFP	162 ± 8	0.09	C: 55	C: 9.4
			G: 81	G: 5.8
CLFP	204 ±11	0.11	C: 60	C: 10.2
			L: 72	L: 5.1

Dynamic light scattering, PDI, and ζ potential measurements conducted in 10 mM NaCl at 25°C for the various multidrug liposomal formulations containing cisplatin. Encapsulation efficiency (% loaded from amount supplied) and mass loading ratio (g/g drug/lipid) as determined by HPLC. D, doxorubicin; A, afatinib; E, erlotinib; G, gefitinib; L, lapatinib; C, cisplatin; F, folate; P, PEG. Corresponding formulations without folate-PEG (FP) are shown in table S1.